Publicaciones en colaboración con investigadores/as de Hospital Universitario Reina Sofia (12)

2022

  1. Correction to: Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry (Rheumatology and Therapy, (2022), 9, 4, (1031-1047), 10.1007/s40744-022-00446-9)

    Rheumatology and Therapy

  2. Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry

    Rheumatology and Therapy, Vol. 9, Núm. 4, pp. 1031-1047

2021

  1. Genetic polymorphisms of ggh and abcc2 are associated with methotrexate intolerance in patients with rheumatoid arthritis

    Journal of Clinical Medicine, Vol. 10, Núm. 18

2020

  1. NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Correction: Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients (The Pharmacogenomics Journal, (2019), 19, 1, (83-96), 10.1038/s41397-018-0057-x)

    Pharmacogenomics Journal

  2. Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients

    Pharmacogenomics Journal, Vol. 19, Núm. 1, pp. 83-96

  3. Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium

    Scientific Reports, Vol. 9, Núm. 1

2016

  1. Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

    Arthritis Research and Therapy, Vol. 18, Núm. 1

2013

  1. Gender-Specific Effects of Genetic Variants within Th1 and Th17 Cell-Mediated Immune Response Genes on the Risk of Developing Rheumatoid Arthritis

    PLoS ONE, Vol. 8, Núm. 8

2012

  1. The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population

    Scandinavian Journal of Rheumatology, Vol. 41, Núm. 1, pp. 10-14

2010

  1. Prediction of functional impairment and remission in rheumatoid arthritis patients by biochemical variables and genetic polymorphisms

    Rheumatology, Vol. 49, Núm. 3, pp. 458-466

2006

  1. Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period

    Arthritis Research and Therapy, Vol. 8, Núm. 1